Literature DB >> 6828268

Management of regional lymph nodes and their prognostic influence in vulvar cancer.

N F Hacker, J S Berek, L D Lagasse, R S Leuchter, J G Moore.   

Abstract

One hundred thirteen patients with invasive carcinoma of the vulva underwent radical vulvectomy and bilateral inguinal-femoral lymphadenectomy between 1957 and 1978. Eighteen had unilateral pelvic lymphadenectomy. Thirty-one patients (27.4%) had positive lymph nodes. The corrected actuarial five-year survival for patients with negative nodes was 96%, whereas it was 94% for patients with one positive node, 80% for those with two positive nodes, and 12% for those with three or more positive nodes. All patients with positive pelvic nodes or pelvic recurrence had three or more positive unilateral groin nodes, and all had palpably suspicious groin nodes preoperatively. Groin and systemic recurrences occurred in 2.9 and 3.8%, respectively, of patients with fewer than three positive unilateral inguinal-femoral nodes, as compared to 33 and 66%, respectively, of patients with three or more positive nodes. These data do not support routine pelvic lymphadenectomy in patients who have no clinically suspicious groin nodes and fewer than three positive nodes on histologic examination.

Entities:  

Mesh:

Year:  1983        PMID: 6828268

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  22 in total

1.  Groin lymphadenectomy with preservation of femoral fascia: total inguinofemoral node dissection for treatment of vulvar carcinoma.

Authors:  Leonardo Micheletti; Fabrizio Bogliatto; Marco Massobrio
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.352

Review 2.  Management of lymph nodes in the treatment of vulvar cancer.

Authors:  Toshiaki Saito; Keiji Kato
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

3.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

4.  The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers.

Authors:  Francesco Giammarile; M Fani Bozkurt; David Cibula; Jaume Pahisa; Wim J Oyen; Pilar Paredes; Renato Valdes Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-08       Impact factor: 9.236

Review 5.  Update on sentinel lymph node evaluation in gynecologic malignancies.

Authors:  Katina Robison; Laura L Holman; Richard G Moore
Journal:  Curr Opin Obstet Gynecol       Date:  2011-02       Impact factor: 1.927

6.  [Changes in the TNM classification of gynecological tumors].

Authors:  L-C Horn; M W Beckmann; A Beller; D Schmidt; U Ulrich; P Hantschmann; C Wittekind
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

7.  [Forms of treatment and results in invasive vulvar cancer].

Authors:  M Lahousen
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

8.  Sentinel Lymph Node Biopsy in Vulvar Cancer Using Combined Radioactive and Fluorescence Guidance.

Authors:  Floris P R Verbeek; Quirijn R J G Tummers; Daphne D D Rietbergen; Alexander A W Peters; Boudewijn E Schaafsma; Cornelis J H van de Velde; John V Frangioni; Fijs W B van Leeuwen; Katja N Gaarenstroom; Alexander L Vahrmeijer
Journal:  Int J Gynecol Cancer       Date:  2015-07       Impact factor: 3.437

9.  Therapy for Primary Vulvar Carcinoma.

Authors:  D Herr; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

10.  Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes.

Authors:  Magdalena Kowalewska; Jakub Radziszewski; Krzysztof Goryca; Mateusz Bujko; Malgorzata Oczko-Wojciechowska; Michal Jarzab; Janusz Aleksander Siedlecki; Mariusz Bidzinski
Journal:  BMC Cancer       Date:  2012-06-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.